CRISPR Therapeutics appoints Siva Sakhamuri as new Chief Technical Officer to advance gene editing and RNA therapies.

CRISPR Therapeutics has named Dr. Siva Sakhamuri as its new Chief Technical Officer, effective immediately. Dr. Sakhamuri brings nearly 30 years of experience in biologics, RNA therapeutics, and vaccine manufacturing, having held leadership roles at companies like Orna Therapeutics and Alnylam Pharmaceuticals. His appointment is aimed at scaling CRISPR's technical operations and manufacturing as the company progresses its gene editing and RNA therapy programs into late-stage clinical development. This move supports CRISPR's mission to develop transformative gene-based medicines for serious diseases, building on its recent success with the first approved CRISPR-based therapy for sickle cell disease and beta thalassemia.

CRISPR Therapeutics (CRSP) trades at USD 51.70 on Pluang as of Nov 02, 2026 20:12 WIB. The stock shows a modest 1-day gain of 0.58%. Its market cap stands at $4.97 billion, reflecting steady investor interest during this leadership transition.